Marinus Pharma (MRNS) Misses Q2 EPS by 4c ; Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Marinus Pharma (MRNS) Misses Q2 EPS by 4c ; Offers Guidance

JMP Securities Reiterates Market Outperform Rating on Marinus Pharmaceuticals (MRNS)

August 13, 2024 4:09 PM EDT

JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).

The analyst comments "Solid ZTALMY growth as we look to key Phase 3 TSC results by mid-4Q24; we reiterate our Market Outperform rating and $10 risk-adjusted,... More

Truist Securities Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)

August 13, 2024 4:04 PM EDT

Truist Securities analyst Joon Lee reiterated a Buy rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).

The analyst comments "2Q24: Ph3 TrustTSC trial remain on track for topline in late Oct/early Nov. Low discontinuation rate of... More